Effect of Intravenous Thrombolysis on Stroke Associated with Atrial Fibrillation

Background: Data based on randomized clinical trials regarding the efficacy and safety of intravenous thrombolysis (IVT) versus placebo or any other antithrombotic agent in the treatment of stroke associated with atrial fibrillation (AF) are unavailable. Methods: Prospectively collected data on AF-associated stroke patients treated in a 3-year period were analyzed to assess the effect of IVT treatment. Outcome measures were modified Rankin Scale (mRS) score for functional outcome, death, and symptomatic intracerebral hemorrhage (sICH). Results: Of 787 patients diagnosed with an acute ischemic stroke in the observed period, 131 (16.6%) had AF. Multivariate logistic regression analysis after adjustment for confounders demonstrated that independent predictors of excellent outcome (mRS 0-1) in patients with AF-associated stroke were lower baseline National Institutes of Health Stroke Scale [NIHSS] score (adjusted odds ratio [adjOR], .87; 95% confidence interval [CI], 0.81-.94; P = .000) and the use of IVT (adjOR, 5.31; 95% CI, 1.90-14.82; P = .001), whereas independent predictors of death were higher baseline NIHSS score (adjOR, 1.07; 95% CI, 1.02-1.12; P = .003), previous stroke (adjOR, 4.11; 95% CI, 1.49-11.35; P = .006), absence of IVT use (adjOR, .19; 95% CI, .05-.77; P = .021), sICH (adjOR, 18.52; 95% CI, 1.59-215.37; P = .020), and higher serum glucose levels (adjOR, 1.26; 95% CI, 1.06-1.50; P = .008). Thrombolyzed patients with AF were less severe at baseline and were less likely to have NIHSS > 18. They were more likely to have excellent and good functional outcome (mRS 0-2) whereas less likely to have death as outcome at 3 months. Thrombolyzed AF patients had constantly lower probability of death regardless of the baseline NIHSS score values. Conclusions: These results should encourage the use of IVT in AF-associated strokes.